Fosun cooperated with foreign-funded enterprises to research and develop new drugs

At the present, Jiangsu Wanbang Biopharmaceutical Co., Ltd (hereinafter called Wanbang Pharma )-a Fosun (600196) controlling backbone enterprise signed an agreement with D-Pham Ltd, a biotechnology company listed in Israel to jointly research and develop and sell medicine DP-b99 to cure acute ischemia stroke in China.

Fosun has always been paying attention to research and development innovation, actively seeking for opportunities and cooperating with internationally famous enterprises. This cooperation is the first time for China local pharmaceutical enterprises to be allowed introducing the new compound approved to be tested in III stage clinical beds. The cooperation between Wanbang Pharma and D-Pham will involve clinical test in China and developing innovative medicines according to FDA and ICH standard, which is a historic breakthrough to Wanbang Pharma.

Wanbang Pharma is a backbone enterprise of Fosun and one of the largest comprehensive antidiabetic drug manufacturing enterprises in China at the present. The animal insulin produced by it is the insulin type sugar reduction medicine which is the only to enter the national basic medicines.

D-Pharm company is the famous research type bio-pharmaceutical company in Israel. It has been appraised as one of the top 100 innovative enterprises in Europe, whose controlling share holders CLAL Group is a comprehensive investment company famous in Israel.